Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 71
Filter
1.
Int J STD AIDS ; 24(7): 587-9, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23970778

ABSTRACT

Primary non-Hodgkin's lymphoma of uterine cervix is a rare diagnosis. We present the case of a 47-year-old woman who presented to our genitourinary (GU) medicine service complaining of a malodorous discharge. Speculum examination revealed a necrotic mass on the cervix. She was referred urgently to gynaecology and subsequent histology revealed a diffuse large B-cell lymphoma. She received six cycles of RCHOP chemotherapy and is now in clinical remission. This case highlights the need for GU medicine physicians to remain vigilant with regard to possible gynaecological malignancies in all of our patients, the need for medical backup within GU medicine clinics and for clear pathways of referral to other specialists to exist.


Subject(s)
Cervix Uteri/pathology , Uterine Cervical Neoplasms/pathology , Antineoplastic Agents/administration & dosage , Biopsy , Colposcopy , Female , Humans , Lymphoma, Large B-Cell, Diffuse/drug therapy , Lymphoma, Large B-Cell, Diffuse/pathology , Magnetic Resonance Imaging , Middle Aged , Neoplasm Staging , Treatment Outcome , Uterine Cervical Neoplasms/drug therapy
2.
HIV Med ; 14(3): 145-52, 2013 Mar.
Article in English | MEDLINE | ID: mdl-22998645

ABSTRACT

OBJECTIVES: The aim of the study was to examine the service use and characteristics of young people diagnosed with HIV infection aged under 25 years in order to design appropriate services. METHODS: A retrospective review of medical records of all individuals diagnosed as HIV positive aged under 25 years at Chelsea and Westminster Hospital, London, UK was carried out. The Health Protection Agency traced all individuals who had been lost to follow-up. We collected demographic, clinical, social and behavioural data. RESULTS: Of the 100 individuals diagnosed as HIV positive aged <25 years, 91% acquired HIV sexually; the median age at diagnosis was 21 years. Fifty-nine per cent were born outside the UK. Of 91 individuals diagnosed in the UK, 20% were diagnosed outside genitourinary medicine. Almost half had tested HIV negative a median of 13 months previously. At HIV diagnosis, 26% had a concurrent sexually transmitted infection; thereafter 34% had a documented risk of HIV transmission. The prevalence of psychiatric comorbidity was high (23%). Cervical screening rates were low; of nine women screened, five required treatment for cervical or vulval neoplasia. One fifth of the cohort were lost to follow-up a median 6 months from diagnosis. CONCLUSIONS: Young people with sexually acquired HIV infection have complex medical and psychosocial needs and many disengage from health services. Current services are not meeting the needs of these young people. Specialist young people's clinics may improve standards of care for this vulnerable group.


Subject(s)
Acquired Immunodeficiency Syndrome/epidemiology , Antiretroviral Therapy, Highly Active , HIV Seropositivity/epidemiology , Health Services Accessibility/statistics & numerical data , Mental Disorders/epidemiology , Needs Assessment , Patient Acceptance of Health Care/statistics & numerical data , Vaginal Smears/statistics & numerical data , Acquired Immunodeficiency Syndrome/drug therapy , Adolescent , CD4 Lymphocyte Count , Female , HIV Seropositivity/drug therapy , HIV Seropositivity/transmission , Health Behavior , Health Knowledge, Attitudes, Practice , Humans , London/epidemiology , Lost to Follow-Up , Male , Mental Disorders/diagnosis , Mental Disorders/therapy , Prevalence , Retrospective Studies , Risk Factors , Viral Load , Vulnerable Populations , Young Adult
3.
BMJ Case Rep ; 20112011 Feb 24.
Article in English | MEDLINE | ID: mdl-22707576

ABSTRACT

The increase in the risk of myocardial infarction can be explained by antiretroviral-induced changes in conventional cardiovascular risk factors. Individual drugs within a drug class vary in their propensity to cause metabolic disturbances, and therefore, further studies are needed to determine the contribution of each drug to cardiovascular risk. A careful stratification of the cardiovascular risk and cardiovascular monitoring of HIV-infected individuals should be performed at baseline and at regular intervals during follow-up for this chronic medical condition. Standard primary and secondary prevention measures should be instituted in accordance with British Guidelines (Heart association, National Institute for Health and Clinical Excellence, etc for lipids, smoking and hypertension) Consideration of cardiovascular risk and drug-drug interactions when prescribing is crucial in the safe and optimum management of these patients. Careful communication between all care providers will help to avoid adverse outcomes.


Subject(s)
Antiretroviral Therapy, Highly Active/adverse effects , Cardiovascular Diseases/chemically induced , Adult , Humans , Male , Risk Factors
4.
Int J STD AIDS ; 21(11): 729-37, 2010 Nov.
Article in English | MEDLINE | ID: mdl-21187352

ABSTRACT

This guideline aims to provide comprehensive information regarding the management of infections caused by Chlamydia trachomatis in European countries. The recommendations contain important information for physicians and laboratory staff working with sexually transmitted infections (STIs) and/or STI-related issues. Individual European countries may be required to make minor national adjustments to this guideline as some of the tests or specific local data may not be accessible, or because of specific laws.


Subject(s)
Chlamydia Infections , Chlamydia trachomatis , Female Urogenital Diseases/microbiology , Male Urogenital Diseases/microbiology , Sexually Transmitted Diseases, Bacterial/microbiology , Europe , Female , Humans , Male , Practice Guidelines as Topic
5.
Int J STD AIDS ; 19(8): 573-4, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18663052

ABSTRACT

We report a case of severe gonococcal ophthalmia and peri-orbital cellulitis in an HIV-positive man without genital infection who was treated successfully in the outpatient department. We also highlight the importance of early diagnosis, treatment and liaison with ophthalmology in order to prevent visual complications.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Ceftriaxone/therapeutic use , Conjunctivitis, Bacterial/drug therapy , Gonorrhea/drug therapy , HIV Infections/complications , Neisseria gonorrhoeae/drug effects , AIDS-Related Opportunistic Infections/diagnosis , AIDS-Related Opportunistic Infections/drug therapy , AIDS-Related Opportunistic Infections/microbiology , Adult , Conjunctivitis, Bacterial/diagnosis , Conjunctivitis, Bacterial/microbiology , Gonorrhea/diagnosis , Gonorrhea/microbiology , Humans , Male , Treatment Outcome
7.
Int J STD AIDS ; 18(6): 427-8, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17609039

ABSTRACT

Post-coital bleeding is a common presenting complaint in the genitourinary medicine clinic. We report an unusual case of recurrent post-coital bleeding secondary to urethral trauma during sexual intercourse.


Subject(s)
Body Piercing/adverse effects , Coitus , Hemorrhage/etiology , Penis , Urethra/injuries , Adult , Female , Humans , Male
9.
Int J STD AIDS ; 17(12): 854-5, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17212866

ABSTRACT

The clinical value of aciclovir, oral or topical, in the episodic treatment of recurrent herpes virus infection is limited. Betadine (povidone-iodine) could provide a cheap, effective alternative for managing symptomatic recurrences. We describe a case where povidone-iodine was used successfully to treat a recurrence of genital herpes simplex and review the literature supporting povidone-iodine in the treatment of genital tract infections.


Subject(s)
Antiviral Agents/therapeutic use , Herpes Genitalis/drug therapy , Herpes Simplex/drug therapy , Povidone-Iodine/therapeutic use , Adult , Female , Herpes Genitalis/virology , Herpes Simplex/etiology , Humans
10.
Sex Transm Infect ; 81(3): 217-9, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15923288

ABSTRACT

BACKGROUND/OBJECTIVES: The burden of new syphilis diagnoses in London has mainly been in men who have sex with men (MSM), many of whom are co-infected with HIV. Our HIV unit introduced regular serological screening for syphilis during routine follow up care to detect patients who may be at risk of asymptomatic infection. We assessed if this remained an effective and necessary strategy in the second year since introduction. METHODS: All HIV outpatients with newly positive syphilis serology between 1 May 2002 and 30 April 2003 were identified using a prospectively collected database. Only patients who were asymptomatic at the time of screening were included (cohort B). They were compared to patients in the exact preceding year (cohort A). RESULTS: 2655 patients had at least one CD4 count measured in the period (surrogate marker for patients having routine follow up bloods), of whom 2389 (90%) had syphilis serology performed. 40 individuals were found to have early asymptomatic infection (two were re-infections), compared to 26 patients in cohort A. These 40 patients represented 36% of all patients with infectious syphilis treated within our department and 56% of those who were HIV positive. The event rate in cohort B was 7.3 per 1000 patient years (CI 5.2 to 9.9) compared to 2.8 (CI 1.8 to 4.0) in cohort A. CONCLUSION: Routine screening is effective and has detected increasing numbers of HIV outpatients with early asymptomatic syphilis. Our department will continue this strategy for all HIV patients during their follow up care. We recommend that other units adopt similar initiatives that assist with regional control of the UK syphilis epidemic.


Subject(s)
HIV Infections/complications , Syphilis Serodiagnosis/standards , Syphilis/diagnosis , Adult , Cohort Studies , Female , Humans , Male , Prospective Studies , Sensitivity and Specificity , Syphilis/complications , Treponema pallidum/isolation & purification
12.
Sex Transm Infect ; 79(3): 257-9, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12794218

ABSTRACT

OBJECTIVES: Syphilis outbreaks have recently been reported in the United Kingdom, some of which have included cohorts of HIV positive individuals. As a result we commenced 3 monthly screening of syphilis serology (STS) for HIV positive patients having routine follow up blood tests. We assessed if there was an increased number of individuals being screened and also whether the screening programme was diagnosing early cases of syphilis. METHODS: Data from a 1 year period following introduction of screening (May 2001) were analysed and compared with data from the same period last year. The case notes of patients with a positive VDRL were reviewed to establish, firstly, whether these represented new diagnoses and, secondly, whether patients were asymptomatic at the time of screening. RESULTS: 2670 patients had at least one CD4 count measured in the period (surrogate for patients having routine bloods). Of these, 2266 patients had STS performed (85%). 38 patients had a positive VDRL. Of these, 20 were confirmed as having early syphilis which was asymptomatic at the time of screening. Six asymptomatic cases were also confirmed with newly positive TPPAs and a negative VDRL. These 26 asymptomatic cases represent 29% of all cases of early syphilis diagnosed in our department and 50% of cases in the HIV positive cohort. CONCLUSION: With intensive surveillance significant numbers of cases of asymptomatic early syphilis are being identified in a group of HIV individuals under routine follow up, at an earlier stage than would otherwise have been the case. This presents an opportunity to intervene not only to prevent clinical illness but also to institute infection control measures.


Subject(s)
AIDS-Related Opportunistic Infections/complications , Mass Screening/organization & administration , Population Surveillance , Syphilis/prevention & control , Adult , Ambulatory Care , Anti-HIV Agents/therapeutic use , CD4 Lymphocyte Count , Cohort Studies , Female , Follow-Up Studies , Humans , Male , Syphilis/complications , Syphilis Serodiagnosis , Time Factors
14.
HIV Med ; 2(4): 272-5, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11737409

ABSTRACT

In a randomized placebo controlled trial 304 HIV infected patients with CD4 cell counts below 350 cells/microL received therapeutic vaccination with: alum placebo (Group I, n = 102), p24-VLP 500 microg (Group II, n = 101) or p24-VLP 1000 microg (Group III, n = 101) p24-VLP monthly for six months. Over one year the average change in CD4 cell count did not differ significantly between groups (-32, -40 and -52 cells per microL respectively). There was also no difference between groups in progression to CDC category B or C events, or in adverse events. Therapeutic vaccination with p24-VLP does not affect CD4 cell decline in patients with advanced HIV infection.


Subject(s)
AIDS Vaccines/immunology , AIDS Vaccines/therapeutic use , HIV Core Protein p24/immunology , HIV Core Protein p24/therapeutic use , HIV Infections/immunology , HIV Infections/therapy , HIV-1 , AIDS Vaccines/administration & dosage , Adult , Anti-HIV Agents/therapeutic use , Antiretroviral Therapy, Highly Active , CD4 Lymphocyte Count , Combined Modality Therapy , Dose-Response Relationship, Drug , Double-Blind Method , Female , Follow-Up Studies , HIV Core Protein p24/administration & dosage , HIV Infections/classification , HIV Infections/mortality , Humans , Male , Severity of Illness Index , Survival Analysis , Time Factors , Treatment Outcome
15.
Drugs Aging ; 16(5): 335-9, 2000 May.
Article in English | MEDLINE | ID: mdl-10917071

ABSTRACT

Vulvovaginal candidiasis (VVC) is a cause of significant morbidity in many women of a childbearing age worldwide. There is a paucity of literature on the prevalence of this condition in postmenopausal women, although it is believed to be uncommon because of the estrogen dependence of VVC. Postmenopausal women who have underlying risk factors for VVC (e.g. hormone replacement therapy, uncontrolled diabetes mellitus, immunosuppression caused by medication or disease) may be at risk of chronic or recurrent VVC. However, as in younger women, it is likely that, even after exhaustive investigations, no cause will be found in a significant number of patients. The investigation and treatment of VVC in older women should be the same as that undertaken in younger women. Both topical and oral preparations are available, but oral regimens are perhaps more acceptable because of the ease of administration and avoidance of potentially messy creams and suppositories. Ketoconazole at a dosage of 400 mg daily for 14 days can be used to achieve clinical remission of symptoms and negative fungal cultures. Induction treatment should be followed by maintenance therapy for 6 months with ketoconazole 100 mg daily, itraconazole 50 to 100 mg daily or fluconazole 100 mg weekly or 150 mg monthly. Short courses of topical therapy, e.g. 500 mg clotrimazole pessaries as a single weekly dose for 6 months or 100mg miconazole pessaries twice weekly for 3 months, followed by once weekly for 3 months may also be used.


Subject(s)
Candidiasis, Vulvovaginal/drug therapy , Candidiasis, Vulvovaginal/diagnosis , Candidiasis, Vulvovaginal/etiology , Chronic Disease , Female , Humans , Middle Aged
16.
AIDS ; 14(5): 561-71, 2000 Mar 31.
Article in English | MEDLINE | ID: mdl-10780719

ABSTRACT

OBJECTIVE: To examine temporal trends (1986-1996) in the CD4 cell count at first HIV-1 positive test and initial AIDS diagnosis, and the influence of selected patient characteristics and treatment factors on these trends. DESIGN: A retrospective clinic-based study. SETTING: Three hospital-based clinics in West London. PATIENTS: A group of 5921 adult HIV-1-seropositive persons and 2835 reported patients with AIDS over a 10-year period from 1 January 1986 to 1 October 1996. METHODS: The CD4 cell count at HIV diagnosis (CD4HIV) was defined as the nearest CD4 cell count to within 2 months of HIV diagnosis; and the CD4 cell count at AIDS diagnosis (CD4AIDS) as the last CD4 cell count in the two months prior to the development of AIDS. Simple and multiple linear regression analysis were used to examine the influence of selected covariates on CD4HIV and CD4AIDS. RESULTS: The percentage of patients with an available CD4HIV and CD4AIDS increased from less than 5% in 1987 to 53% and 40%, respectively, in 1990, and 79% and 48%, respectively, in 1996. Patients with a missing CD4HIV or CD4AIDS were younger and less likely to have received antiretroviral therapy or prophylaxis for Pneumocystis carinii pneumonia (PCP). There was no significant change in CD4HIV over a 10-year period (median 334 x 10(6) cells/l), but a lower CD4HIV was associated with older age at presentation and injecting drug use. There was a delay in the onset of clinical AIDS, with a fall in the median CD4AIDS value from 99 x 10(6) cells/l prior to 1987, to 58 x 10(6) cells/l in 1990, 68 x 10(6) cells/l in 1994 and 60 x 10(6) cells/l in 1996; this decline in onset was seen for PCP as well as for cytomegalovirus and atypical mycobacterial infections. At all time periods, a lower CD4AIDS was associated with combined use of antiretroviral therapy and PCP prophylaxis. After adjustment for use of antiretroviral therapy and PCP prophylaxis prior to AIDS diagnosis, year of diagnosis was no longer associated with CD4AIDS. There was a significant trend towards an improved survival following AIDS diagnosis from 20.1 months prior to 1988, to 20.3 months (1989-1990), 21.0 months (1991-1992) and 22.1 (1993-1994) (P < 0.0005). CONCLUSIONS: The observed decline in CD4AIDS value was related to the introduction of antiretroviral therapy in 1988, and PCP prophylaxis in 1989. Temporal changes in the CD4 cell count at HIV and AIDS diagnosis among different demographic groups can provide insights into the changing natural history of the HIV epidemic and access to medical care. We recommend monitoring of the CD4 cell count at new HIV and AIDS diagnosis and at initiation of antiretroviral therapy as additional measures in national HIV/AIDS surveillance.


Subject(s)
Acquired Immunodeficiency Syndrome/immunology , CD4 Lymphocyte Count , HIV Infections/immunology , HIV Seropositivity/immunology , HIV-1 , Population Surveillance , Acquired Immunodeficiency Syndrome/drug therapy , Acquired Immunodeficiency Syndrome/epidemiology , Adult , Age Factors , Anti-HIV Agents/therapeutic use , Female , HIV Infections/drug therapy , HIV Infections/epidemiology , Heterosexuality , Homosexuality, Male , Humans , London/epidemiology , Male , Retrospective Studies , Risk Factors , Sex Factors , Substance Abuse, Intravenous , Survival Analysis , Zidovudine/therapeutic use
17.
Int J STD AIDS ; 11(12): 767-73, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11138909

ABSTRACT

To date the management of HIV-positive women regarding the prevention of cervical cancer remains controversial. There are different approaches to cervical screening in different health authorities in the UK and worldwide due to different funding and healthcare provision in general, the official disease prevalence and the attempt to tailor the screening programme according to a perceived risk for the population covered, but most of all in the diverse evidence provided to aid the development of a screening programme. The advent of high active antiretroviral therapy (HAART) may also have altered the natural history of cervical intraepithelial neoplasia (CIN) before it became sufficiently understood and future studies have to take this into account when investigating the impact of human papillomavirus (HPV) and CIN on the risk of developing cervical cancer. This article aims to summarize the available evidence to date and provide a basis on which an effective and acceptable screening programme for HIV-positive women can be developed.


Subject(s)
HIV Infections/complications , Mass Screening , Uterine Cervical Dysplasia/diagnosis , Uterine Cervical Neoplasms/diagnosis , Vaginal Smears , Antiretroviral Therapy, Highly Active , CD4 Lymphocyte Count , Colposcopy , Female , HIV Infections/drug therapy , HIV Infections/immunology , HIV Seropositivity/complications , HIV Seropositivity/drug therapy , HIV Seropositivity/immunology , Humans , Papillomaviridae/isolation & purification , Papillomavirus Infections/epidemiology , Papillomavirus Infections/virology , Polyomaviridae , Prevalence , Tumor Virus Infections/epidemiology , Tumor Virus Infections/virology , Uterine Cervical Neoplasms/epidemiology , Uterine Cervical Neoplasms/etiology , Uterine Cervical Dysplasia/epidemiology , Uterine Cervical Dysplasia/etiology
18.
Int J STD AIDS ; 10(11): 755-8, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10563567

ABSTRACT

The purpose of this audit was to assess the prevalence of cervical pathology and clinical outcome in HIV-infected women as well as adherence to local screening guidelines. As there are no national screening guidelines for HIV-positive patients, recommendations vary widely. At St Stephen's Centre, these included annual cytology and a baseline colposcopy. We audited this recommendation by a clinical notes review using a computer database. Analysis was performed using Statistical Package for Social Sciences (SPSS). Two hundred and twenty-two patients were eligible for analysis, their mean age was 33.6 years, median CD4 count was 239 and median viral load was 7836 RNA copies. Cytology was undocumented in 72 women (32.4%), while overall 42 (28%) smears of the remaining 150 patients were abnormal: borderline 17.3%, mild dyskaryosis 4.6%, moderate dyskaryosis 4%, severe dyskaryosis 2%. The results were normal in 64% and unsatisfactory in 4.6%. Colposcopy was offered to 93 (42%) women who attended at least once in 71 cases (32%). Thirty-one women had biopsies taken (43.6% of all colposcopies). Twenty-four (77.4%) had a histology more severe than HPV and 15 (48.4%) more severe than cervical intraepithelial neoplasia (CIN)-1. Overall, 49.7% had management not complying with the guidelines. This audit led to a critical literature review and of local screening guidelines. A computer aided reminder program has now been installed and re-auditing of the management of HIV-positive women is planned.


Subject(s)
Colposcopy/standards , HIV Seropositivity , Hospitals, Teaching/standards , Medical Audit , Vaginal Smears/standards , Adolescent , Adult , Female , Humans , London , Mass Screening/standards , Middle Aged , Quality Control
SELECTION OF CITATIONS
SEARCH DETAIL
...